Research Article

Efficacy of Rosuvastatin Combined with rt-PA Intravenous Thrombolytic Therapy for Elderly Acute Ischemic Stroke Patients

Jianzhong Zhu,1 Shan Wang,2 Zhenqiu Chen,1 and Qiqi Cheng1

1Department of Neurology, Longmen County People’s Hospital, Huizhou 516800, Guangdong Province, China
2Department of Cardiovascular Medicine, Longmen County People’s Hospital, Huizhou 516800, Guangdong Province, China

Correspondence should be addressed to Jianzhong Zhu; zhujianzhong7895@163.com

Received 16 March 2022; Revised 7 May 2022; Accepted 23 May 2022; Published 15 June 2022

Academic Editor: Min Tang

Copyright © 2022 Jianzhong Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acute ischemic stroke (AIS) is a fatal and disabling disease. Given the unsatisfactory results by current treatment strategies, optimizing the treatment of AIS is still an urgent problem to be solved. Objective. To determine the therapeutic efficacy of rosuvastatin (ROS) combined with thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) on senile AIS patients and analyze its effects on serum inflammatory responses and neurological function. Methods. A retrospective study was conducted on 150 senile AIS patients who visited the Longmen County People’s Hospital between January 2019 and June 2021. Of them, 100 cases treated by ROS combined with rt-PA intravenous thrombolytic therapy (ivTT) were set as the observation group and the rest 50 cases receiving rt-PA alone were included in the control group. Intergroup comparisons were conducted with respect to the following parameters: neurological function (National Institutes of Health Stroke Scale, NIHSS; Scandinavian Stroke Scale, SSS), serum neuron-specific enolase (NSE) and high-sensitivity C-reactive protein (hs-CRP), therapeutic efficacy, incidence of adverse reactions, and patient satisfaction. Results. The observation group had lower NIHSS and SSS scores and serum NSE and hs-CRP than the control group. In addition, the observation group was found with a higher overall response rate, higher patient satisfaction, and fewer adverse reactions. Conclusion. ROS combined with rt-PA ivTT can better enhance the therapeutic efficacy of elderly patients with AIS, improve their neurological function, and reduce serum inflammatory responses.

1. Introduction

Stroke is a fatal disease that accounts for 5% of disability and 10% of deaths worldwide [1, 2], of which approximately 80% are ischemic strokes [3, 4]. Acute ischemic stroke (AIS) is most prevalent, which can lead to disability due to adverse events such as ischemic injury and neuronal cell death [5]. The risk of this common cardiocerebrovascular disease increases with age [6, 7]. According to epidemiological data, the global incidence of stroke increased by 70-85% from 1990 to 2019, and the number of deaths increased by nearly 45%, with about 795,000 people in the United States being affected by the disease every year [8]. Stroke is attributed to intracranial vascular occlusion induced by atherosclerosis, which prevents blood from flowing into a part of the brain, leading to ischemic necrosis of this part of brain tissue [9, 10].

The prognosis of stroke is poor in middle-aged and elderly patients [11, 12]. Besides, such a disease will not only significantly lower the quality of life of patients but also affect their normal movement function and even consciousness, eventually leading to disability or death [13, 14]. Therefore, the treatment of stroke has always been an important direction of clinical research.

Clinically, statins are commonly used to treat cardiovascular diseases because of their cholesterol-lowering effect on blood vessels, as well as antiangina pectoris and anti-ischemic properties [15]. They can inhibit the formation of mevalonate pathway and isoprenoid, prevent endothelial ischemia-reperfusion injury, improve endothelial function, enhance ischemic vasodilation, and relieve inflammation [16]. Among them, rosuvastatin (ROS) has an obvious inhibitory effect on inflammatory factors [17]. Recombinant tissue plasminogen activator (Alteplase) (rt-PA), another
commonly used drug in cardiocerebrovascular diseases, is a serine protease that can cleave plasminogen to activate plasmin. Although it plays an important role in cardiovascular diseases, its toxicity is prone to cause a series of complications and even ischemia-reperfusion injury after revascularization [18]. Yang et al. [19] reported that ROS combined with rt-PA for patients with AIS, no matter high or low dose of ROS, had no significant effect on their functional outcomes at 3 months, and the safety was comparable. However, the comparative analysis of ROS combined with rt-PA and rt-PA alone in the treatment of AIS is still limited.

Given that there are few related studies on the combination of these two drugs in treating ischemic stroke, we analyzed the effectiveness of the combination therapy for elderly AIS patients. In addition, the novelty of this research lies in the comprehensive comparison and evaluation of the effectiveness and reliability of the combination of the two drugs in the treatment of AIS from the aspects of neurological function, inflammation-related serum indexes, clinical efficacy, safety, and treatment satisfaction, which provides a reliable theoretical reference for AIS treatment.

2. Methods

2.1. General Information. This retrospective study selected 150 elderly AIS patients who visited the Longmen County People's Hospital between January 2019 and June 2021 and assigned them to observation (n = 100) and control (n = 50) groups. The general data of the two cohorts were balanced and comparable (P > 0.05). The Ethics Committee at the Longmen County People's Hospital approved this research, and patients and their families agreed and signed the informed consent.

Inclusion criteria are as follows: (1) diagnosis of AIS in our hospital; (2) age > 60; (3) single lesion; (4) first episode, with onset-to-thrombolysis time less than 4.5 h; and (5) duration of symptoms and signs of brain dysfunction > 1 h. Exclusion criteria are as follows: (1) presence of intracranial hemorrhage as indicated by CT examination; (2) history of stroke and major head trauma within the last 3 months; (3) tendency of active bleeding focus or bleeding; (4) intracranial tumors, aneurysms, and arteriovenous malformations; (5) recent use of systematic anticoagulant, thrombolytic, and fibrinolytic treatments; (6) organic diseases of liver, kidney, heart, and other organs; and (7) mental system, immune system, and blood system diseases.

2.2. Methods. Before treatment, all patients were given routine treatment, including reducing blood sugar, lowering blood pressure, anti-infection, nourishing nerves, and correcting acid-base and water-electrolyte disorders. Based on that, the control group received intravenous thrombolytic therapy (ivTT) with rt-PA (Boehringer Ingelheim International GmbH, Germany, Import Drug Registration Certificate Nos.: S20110051 and S20110052), with a total dose of 0.9 mg/kg and a maximum of ≤90 mg; 10% of the drug was administered as a single iv bolus within 1 min, and the remaining 90% was given by continuous iv drip within 1 h. The observation group was given ROS (Sincere Pharmaceutical Group Limited, Nanjing, China, SFDA Approval No.: H20113246) in addition to rt-PA ivTT and routine treatment. The thrombolytic therapy was given with the same method and dosage as mentioned in the control group, and in addition to that, oral administration of ROS was given 15 mg/time, once a day for one month after ivTT.

2.3. Outcome Measures

2.3.1. National Institutes of Health Stroke Scale (NIHSS) and Scandinavian Stroke Scale (SSS) Scores. The neurological recovery and limb function of patients were analyzed and compared at admission and one month posttreatment. The NIHSS [20] and SSS [21] were used to evaluate patients' neurological function recovery, with lower scores indicating better recovery.

2.3.2. Serum Factors Neuron-Specific Enolase (NSE) and High-Sensitivity C-Reactive Protein (hs-CRP). The measurement of serum NSE and hs-CRP was conducted upon admission and 3 days after treatment, using human NSE and human hs-CRP ELISA kits (Shanghai Yuanmu Biotechnology Co., Ltd., YM-SZ0162, YM-SZ0895), respectively. All related operations were completed by the hospital’s professional testing personnel following the instrument and kit instructions.

2.3.3. Curative Effect. The efficacy of patients was evaluated one month after treatment as follows: ineffectual: an increase in NIHSS score or a decrease <18%; effective: decreased NIHSS score by 18%-45% compared with the pretreatment score; markedly effective: decreased NIHSS score by 46%-90% with disability grades 1-3; and clinically cured: a decrease of NIHSS by 91%-100%, with disability grade 0.

2.3.4. Adverse Reactions (ARs). The ARs occurred during treatment, such as gastrointestinal dysfunction, urinary incontinence, mild elevation of alanine aminotransferase, and poststroke dementia, were counted and compared.

2.3.5. Treatment Satisfaction. Patients’ satisfaction testing used a self-made treatment satisfaction questionnaire (total: 100 points), and satisfaction scores were compared. The test content and evaluation criteria were self-made. Evaluation criteria are as follows: 85-100: satisfied, 70-85: basically satisfied, and <70: dissatisfied.

2.4. Statistical Methods. Data were statistically processed by SPSS19.0 (Asia Analytics Formerly SPSS China), and differences with P < 0.05 were deemed significant. Count data were tested by χ². The intergroup comparison of quantitative data denoted by X ± S was made by the t test, and the intragroup comparison before and after treatment was carried out using the paired t test. GraphPad Prism 8 (GraphPad Software, San Diego, USA) was used for image rendering.
3. Results

3.1. General Information. The intergroup comparison showed no obvious differences in a series of general information such as gender, age, BMI, smoking, and drinking (P > 0.05) Table 1.

3.2. NIHSS and SSS Scores. After investigation, it was found that the NIHSS and SSS scores changed significantly in both groups after treatment, and these scores were lower in the observation group as compared to the control group (P < 0.05) Figure 1.

3.3. Serum NSE and hs-CRP Levels. The detection of serum NSE and hs-CRP levels revealed that the two indexes had significant changes in both groups after treatment. After treatment, the two indexes decreased statistically in the two groups (P < 0.05) and were lower in the observation group (P < 0.05) Figure 2.

3.4. Efficacy. The comparison of posttreatment efficacy revealed a higher total effective rate in the observation group when compared to the control group (P < 0.05) Table 2.

3.5. Incidence of ARs. The comparison of ARs revealed a significantly lower incidence of ARs in the observation group compared with the control group (P < 0.05) Table 3.

3.6. Treatment Satisfaction. The intergroup comparison of treatment satisfaction showed higher patient satisfaction in the observation group as compared to the control group (P < 0.05) Table 4.

4. Discussion

The choice regarding the treatment of AIS, a disease with high mortality, is undoubtedly essential [22]. It is wise to use thrombolytic drugs to treat such a cardiocerebrovascular disease [23]. In this section, we will analyze the effects of ROS combined with rt-PA ivTT on elderly patients with AIS based on the results obtained here and related literature.

First, the overall efficacy was statistically higher in the observation group when compared to the control group. Al-Kuraishy et al. [24] pointed out in their study that the application of ROS in AIS patients has certain efficacy, which can improve the cardiac metabolism of patients and lower the risk of stroke recurrence. Lu et al. [25] also confirmed the effectiveness of ROS in AIS in animal experiments, mainly reflected in the prevention of blood-brain barrier damage. In addition, obviously improved neurological function was found in both groups after treatment, with lower NIHSS and SSS scores in the observation group. It suggests that the observation group achieved better outcomes due to better neurological recovery. Similarly, M. Safakheil and H. Safakheil [26] reported that ROS has a protective effect on the neurological function of AIS model rats, and this protective mechanism is related to the reversal of oxidative stress imbalance in the body. Cerebral infarction will cause ischemic injury of the brain, followed by vasoconstriction and blood flow reduction induced by inflammatory factors, resulting in endothelial cell injury in the brain area, which will greatly damage the nerve function [27]. Therefore, neurological function is closely associated with the severity and treatment effect of stroke. The rt-PA used in this study is a common rapid thrombolytic therapy, which can achieve the effect of thrombolysis by catalysing probrinolysin into active fibrinolytic enzyme. However, if this operation is not completed in a short period of time, it will not only lead to poor effects but also bring a series of adverse symptoms [28]. Relevant research on coronary heart disease has found that ROS, with a potent inhibitory effect on related pathways, also has a good effect on vascular endothelial relaxation [29]. Therefore, in this study, the observation group was first given rt-PA for thrombolytic therapy, and then, ROS was applied for vascular endothelial relaxation, which may explain the better recovery of brain endothelial cell damage and higher treatment efficacy in the observation group.

From the perspective of serum-related factors, this study found that although serum hs-CRP was improved to varying degrees in both groups, the improvement was better in the observation group. Previous studies have confirmed that ROS can significantly reduce neuroinflammation after rt-PA treatment in the AIS mouse model and play a protective role in neurological function by exerting anti-inflammatory effects [30]. The role of statins is to inhibit the Rho/ROCK pathway by inhibiting the formation of isoprenoid intermediates, thus increasing the synthesis of endothelial NO, reducing the contraction and proliferation of vascular smooth muscle cells to reduce the formation of thrombosis, and inhibiting a series of cytokines such as inflammatory factors [31]. hs-CRP, an important marker of the body’s inflammatory response, is an acute phase protein synthesized by liver cells in the early stage of inflammation. Due to the damage of DE1 vascular endothelial cells in acute cerebral infarction patients, hs-CRP concentration will be significantly increased [32]. Besides, a study on encephalitis found that the level of NSE was closely related to inflammation, and increased levels were associated with more severe

| Classification | Observation group (n = 100) | Control group (n = 50) | t/χ² | P |
|----------------|-----------------------------|------------------------|------|---|
| Gender         |                             |                        |      |   |
| Male           | 69 (69.00)                  | 33 (66.00)             |      |   |
| Female         | 31 (31.00)                  | 17 (34.00)             |      |   |
| Age (years)    | 68.65 ± 3.48                | 68.28 ± 3.89           | 0.59 | 0.556 |
| BMI (kg/m²)    | 23.69 ± 3.42                | 23.37 ± 3.65           | 0.53 | 0.598 |
| Residence      |                             |                        |      |   |
| Urban          | 66 (66.00)                  | 34 (68.00)             |      |   |
| Rural          | 34 (34.00)                  | 16 (32.00)             |      |   |
| Drinking       |                             |                        |      |   |
| Yes            | 73 (73.00)                  | 36 (72.00)             |      |   |
| No             | 27 (27.00)                  | 14 (28.00)             |      |   |
| Smoking        |                             |                        |      |   |
| Yes            | 69 (69.00)                  | 33 (66.00)             | 0.014 | 0.710 |
| No             | 31 (31.00)                  | 17 (34.00)             |      |   |
inflammation [33]. Combined with our findings, the additional use of ROS may explain better alleviation of inflammatory responses in the observation group.

This study still has some shortcomings. Although patient satisfaction was investigated in this research, we were unable to investigate patients’ quality of life and the improvement of specific limb function and psychological anxiety level after treatment due to time constraints. In addition, this is a single-center small sample study, which may have some impact on the accuracy and universality of the reported results. Finally, there is no analysis regarding the long-term follow-up of patients, which if supplemented, will help further understand the impact of the two regimens on the long-term outcomes of these patients. In future research, we will supplement other indicators to improve the research and evaluate patients’ quality of life after treatment, so as to optimize the therapeutic scheme to find a new and effective treatment for AIS in the elderly.
5. Conclusion

To sum up, ROS combined with rt-PA ivTT contributes to higher curative effects in senile AIS patients, improves neurological function, and reduces serum inflammatory responses.

Data Availability

The simulation experiment data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing interests.

References

[1] S. I. Hay, A. A. Abajobir, K. H. Abate et al., “Global regional and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories 1990–2016: a systematic analysis for the global burden of disease study 2016,” Lancet, vol. 390, no. 10100, pp. 1260–1344, 2017.
[2] T. Vos, C. Allen, M. Arora, and R. M. Barber, “A systematic analysis for the global burden of disease study 2016,” Lancet, vol. 390, no. 2017, pp. 1151–1201, 2017.
[3] E. K. Aldous, S. M. Toor, A. Parry et al., “Identification of novel circulating miRNAs in patients with acute ischemic stroke,” International Journal Of Molecular Sciences, vol. 23, article 3387, 2022.
[4] T. K. Karikari, A. Charway-Felli, K. Hoglund, K. Blennow, and H. Zetterberg, “Commentary: global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the global burden of disease study 2015,” Frontiers in Neurology, vol. 9, p. 201, 2018.
[5] G. Wang, Y. Zhou, T. Zhong, A. Song, and Q. Xue, “The role of blood Inc-ZFAS1 in acute ischemic stroke: correlation with neurological impairment, inflammation, and survival profiles,” Journal of Clinical Laboratory Analysis, vol. 36, no. 2, article e24219, 2022.
[6] X. Zhang, S. Chen, K. Lai, Z. Chen, J. Wan, and Y. Xu, “Machine learning for the prediction of acute kidney injury in critical care patients with acute cerebrovascular disease,” Renal Failure, vol. 44, no. 1, pp. 43–53, 2022.
[7] B. M. Kissela, J. C. Khoury, K. Alwell et al., “Age at stroke: temporal trends in stroke incidence in a large, biracial population,” Neurology, vol. 79, no. 17, pp. 1781–1787, 2012.
[8] Y. Ou, F. Yang, F. Meng et al., “Plasma concentration of tumor necrosis factor-stimulated gene-6 as a novel diagnostic and 3-month prognostic indicator in non-cardioembolic acute ischemic stroke,” Frontiers in Immunology, vol. 13, p. 713379, 2022.
[9] L. Catanese, J. Tarsia, and M. Fisher, “Acute ischemic stroke therapy overview,” Circulation Research, vol. 120, no. 3, pp. 541–558, 2017.
[10] J. Puyal, V. Ginet, and P. G. Clarke, “Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection,” Progress in Neurobiology, vol. 105, pp. 24–48, 2013.
[11] B. Zhang, D. Wang, T. F. Ji, L. Shi, and J. L. Yu, “Overexpression of IncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-kappab signaling pathway in a rat model,” Oncotarget, vol. 8, no. 10, article 17347–17357, 2017.
[12] W. Li, C. Jin, A. Vaidya et al., “Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: a prospective study,” Hypertension, vol. 70, no. 3, pp. 506–514, 2017.
[13] I. P. Hsueh, C. H. Wang, T. H. Liou, C. H. Lin, and C. L. Hsieh, “Test-retest reliability and validity of the comprehensive activities of daily living measure in patients with stroke,” Journal of Rehabilitation Medicine, vol. 44, no. 8, pp. 637–641, 2012.
[14] A. Azad, T. Mohammadinezhad, G. Taghizadeh, and L. Lajevardi, “Clinical assessment of activities of daily living in acute stroke: validation of the Persian version of Katz Index,” Medical Journal of the Islamic Republic of Iran, vol. 31, article 30, 2017.
[15] D. Tousoulis, C. Psarros, M. Demosthenous, R. Patel, C. Antoniades, and C. Stefanadis, “Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins,” Journal of the American College of Cardiology, vol. 63, no. 23, pp. 2491–2502, 2014.
[16] J. A. Lardizabal and P. C. Deedwania, “The anti-ischemic and anti-anginal properties of statins,” Current Atherosclerosis Reports, vol. 13, no. 1, pp. 43–50, 2011.
[17] L. Zhang, S. Zhang, Y. Yu, H. Jiang, and J. Ge, “Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol,” Herz, vol. 45, no. 6, pp. 594–602, 2020.

[18] P. M. Chen, D. M. Meyer, and B. C. Meyer, “Encephalopathy only stroke codes (EoSC) do not result in rt-PA treatments,” Journal of Stroke and Cerebrovascular Diseases, vol. 29, no. 9, p. 105022, 2020.

[19] W. Y. Yang, Y. F. Li, Z. R. Wang et al., “Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the inspire randomized clinical trial,” Journal of Neurology, vol. 268, no. 7, pp. 2560–2569, 2021.

[20] D. Runde, “Calculated decisions: NIH stroke scale/score (NIHSS),” Emergency Medicine Practice, vol. 22, no. 7, pp. -CD6–CD7, 2020.

[21] P. W. Stubbs and J. Mortensen, “Clinimetrics: the Scandinavian Stroke Scale,” Journal of Physiotherapy, vol. 66, no. 2, p. 132, 2020.

[22] S. Vidale, A. Consoli, M. Arnaboldi, and D. Consoli, “Postischemic inflammation in acute stroke,” Journal of Clinical Neurology, vol. 13, no. 1, pp. 1–9, 2017.

[23] A. A. Wang, L. Li, Y. Li, L. Miao, Y. H. Pan, and J. X. Liu, “Research progress on Chinese medicinal material-derived active polypeptides against ischemic cardiovascular and cerebrovascular diseases,” Zhongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi= China Journal of Chinese Materia Medica, vol. 46, no. 21, pp. 5576–5584, 2021.

[24] H. M. Al-Kuraishy, A. I. Al-Gareeb, and M. T. Najj, “Statin therapy associated with decreased neuronal injury measured by serum S100β levels in patients with acute ischemic stroke,” International Journal of Critical Illness and Injury Science, vol. 11, no. 4, pp. 246–252, 2021.

[25] D. Lu, H. C. Mai, Y. B. Liang, B. D. Xu, A. D. Xu, and Y. S. Zhang, “Beneficial role of rosuvastatin in blood-brain barrier damage following experimental ischemic stroke,” Frontiers in Pharmacology, vol. 9, p. 926, 2018.

[26] M. Safakheil and H. Safakheil, “The effect of exosomes derived from bone marrow stem cells in combination with rosuvastatin on functional recovery and neuroprotection in rats after ischemic stroke,” Journal of Molecular Neuroscience, vol. 70, no. 5, pp. 724–737, 2020.

[27] R. Dymarek, K. Ptaszkowski, L. Slupska, T. Halski, J. Taradaj, and J. Rosinczuk, “Effects of extracorporeal shock wave on upper and lower limb spasticity in post-stroke patients: a narrative review,” Topics in Stroke Rehabilitation, vol. 23, no. 4, pp. 293–303, 2016.

[28] M. Castellanos, C. van Eendenburg, C. Gubern et al., “Low levels of caveolin-1 predict symptomatic bleeding after thrombolytic therapy in patients with acute ischemic stroke,” Stroke, vol. 49, no. 6, pp. 1525–1527, 2018.

[29] M. S. Ellulu, I. Patimah, H. Khaza’ai, A. Rahmat, Y. Abed, and F. Ali, “Atherosclerotic cardiovascular disease: a review of initiators and protective factors,” Inflammopharmacology, vol. 24, no. 1, pp. 1–10, 2016.

[30] D. Lu, Y. Liu, H. Mai et al., “Rosuvastatin reduces neuroinflammation in the hemorrhagic transformation after rt-PA treatment in a mouse model of experimental stroke,” Frontiers in Cellular Neuroscience, vol. 12, p. 225, 2018.

[31] N. Sawada and J. K. Liao, “Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis,” Antioxidants & Redox Signaling, vol. 20, no. 8, pp. 1251–1267, 2014.

[32] J. Shan, H. Jin, and Y. Xu, “T cell metabolism: a new perspective on Th17/Treg cell imbalance in systemic lupus erythematosus,” Frontiers in Immunology, vol. 11, p. 1027, 2020.

[33] P. Czupryna, S. Grygorczuk, S. Pancewicz et al., “Evaluation of NSE and S100B in patients with tick-borne encephalitis,” Brain and Behavior: A Cognitive Neuroscience Perspective, vol. 8, no. 12, article e01160, 2018.